2-氨基-3-硝基-6-氯吡啶 | 27048-04-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 2-氨基-3-硝基-6-氯吡啶
• 中文别名: 2-氨基-6-氯-3-硝基吡啶；6-氯-3-硝基吡啶-2-胺
• 英文名称: 2-amino-6-chloro-3-nitropyridine
• 英文别名: 6-amino-2-chloro-5-nitropyridine；6-chloro-3-nitropyridin-2-amine；2-amino-3-nitro-6-chloropyridine
• CAS: 27048-04-0
• 化学式: C₅H₄ClN₃O₂
• mdl: MFCD00044350
• 分子量: 173.559
• InChiKey: WERABQRUGJIMKQ-UHFFFAOYSA-N

物化性质

• 熔点：
  195-196
• 沸点：
  339.9±37.0 °C(Predicted)
• 密度：
  1.596±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿、二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  84.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xi
• 安全说明：
  S22,S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090
• 危险品运输编号：
  2811
• 包装等级：
  Ⅲ
• 危险类别：
  6.1
• 危险性防范说明：
  P261,P301+P312,P302+P352,P304+P340,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  Refrigerator

SDS

Name:	2-Amino-6-Chloro-3-Nitropyridine 97% Material Safety Data Sheet
Synonym:	None
CAS:	27048-04-0

Section 1 - Chemical Product MSDS Name:2-Amino-6-Chloro-3-Nitropyridine 97% Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
27048-04-0	2-Amino-6-Chloro-3-Nitropyridine	97	248-188-5

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas.
Extinguishing Media:
In case of fire, use water, dry chemical, chemical foam, or alcohol-resistant foam. Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Wash clothing before reuse.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 27048-04-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: yellow
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 188.00 - 193.00 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: N/A
Explosion Limits, upper: N/A
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H4ClN3O2
Molecular Weight: 173.56

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 27048-04-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Amino-6-Chloro-3-Nitropyridine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 27048-04-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 27048-04-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 27048-04-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质：黄色结晶粉末，熔点为171-172℃。该物质不溶于热水，仅微溶于醇和醚。

反应信息

• 作为反应物：
  描述：

  2-氨基-3-硝基-6-氯吡啶 在 盐酸 、 tin(II) chloride dihdyrate 、 三乙胺 作用下， 以 1,4-二氧六环 、 水 、 异丙醇 为溶剂， 反应 6.0h， 生成 氟吡汀
  参考文献：
  名称：

  通过增强自噬和诱导抗凋亡蛋白B细胞淋巴瘤2（Bcl-2）赋予神经保护活性的氨基甲酸酯的发现。

  摘要：

  神经退行性疾病具有某些病理生理学特征，这些特征代表了药物发现的共同目标。特别是，蛋白稳态失调和由此导致的神经元凋亡死亡代表了药理干预的常见途径。合成了基于临床可用药物氟吡汀的芳香族氨基甲酸酯衍生物库，以确定神经保护活性的结构-活性关系。鉴定出几种衍生物，它们在人诱导的多能干细胞衍生的神经元中具有更大的保护作用，可在低至100 nM的浓度下保护高达80％的神经元免受依托泊苷诱导的凋亡。所开发的芳族氨基甲酸酯具有中枢神经系统治疗剂所需的理化性质。亲本支架的主要已知作用机制与观察到的神经保护活性无关。在本文中，我们证明了神经保护性芳香族氨基甲酸酯的功能是将Bcl-2 / Bax比值提高至抗凋亡状态，并通过诱导Beclin 1激活自噬。

  DOI：

  10.1021/acs.jmedchem.7b01199
• 作为产物：
  描述：

  2,6-二氯吡啶 在 ammonium hydroxide 、 硫酸 、 硝酸 作用下， 以 异丙醇 为溶剂， 反应 72.0h， 生成 2-氨基-3-硝基-6-氯吡啶
  参考文献：
  名称：

  与钾KV7通道开放活性有关但与肝细胞毒性无关的止痛药氟吡汀N修饰衍生物的氧化电位

  摘要：

  神经元电压门控性钾离子通道（K V）的开放剂作为治疗疼痛（氟吡汀）和癫痫病（瑞替加滨）的治疗剂受到关注。为了更好地了解氟吡汀的作用机理和毒性，我们合成了九种具有不同氧化还原行为的新型类似物。氟吡汀可被氧化代谢为氮杂醌二亚胺；因此，通过循环伏安法测定了氟吡汀及其类似物的氧化电位。K V 7.2 / 3（KCNQ2 / 3）打开活性是通过已建立的测定法来确定的，这些测定法过度表达了这些通道的HEK293细胞。发现化合物的氧化电位与其EC 50之间存在联系钾通道开放活性的数值。另一方面，在转基因小鼠肝细胞（TAMH）的培养物中，氧化电位与细胞毒性之间没有相关性。这些结果支持了氟吡汀的氧化代谢产物有助于作用机理的想法，类似于最近对乙酰氨基酚（对乙酰氨基酚）的提议，但对肝毒性没有影响。

  DOI：

  10.1002/cmdc.201402442

文献信息

• [EN] BICYCLIC INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS BICYCLIQUES DE L'HISTONE DÉSACÉTYLASE
  申请人：RODIN THERAPEUTICS INC

  公开号：WO2020014602A1

  公开（公告）日：2020-01-16

  Provided herein are compounds of Formula I and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone deacetylases (HDAC).

  本文提供了公式I的化合物及其药用盐和组合物，这些化合物对治疗与组蛋白去乙酰化酶（HDAC）相关的各种疾病条件有用。
• N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
  申请人：——

  公开号：US20020165241A1

  公开（公告）日：2002-11-07

  Compounds represented by Formula (I): 1 or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

  由化学式（I）表示的化合物及其药学上可接受的盐，可作为NMDA NR2B拮抗剂，用于缓解疼痛。
• [EN] NOVEL COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION<br/>[FR] NOUVEAUX COMPOSÉS POUR LE TRAITEMENT DE MALADIES LIÉES À L'EXPRESSION DE DUX4
  申请人：FACIO INTELLECTUAL PROPERTY B V

  公开号：WO2021105481A1

  公开（公告）日：2021-06-03

  The present invention relates to compounds that act as DUX4 repressors, suitable for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.

  本发明涉及作为DUX4抑制剂的化合物，适用于治疗与DUX4表达相关的疾病，如肌肉萎缩症。它还涉及使用这些化合物，或者使用这些化合物的方法。
• Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3
  作者：Allan S. Wagman、Rustum S. Boyce、Sean P. Brown、Eric Fang、Dane Goff、Johanna M. Jansen、Vincent P. Le、Barry H. Levine、Simon C. Ng、Zhi-Jie Ni、John M. Nuss、Keith B. Pfister、Savithri Ramurthy、Paul A. Renhowe、David B. Ring、Wei Shu、Sharadha Subramanian、Xiaohui A. Zhou、Cynthia M. Shafer、Stephen D. Harrison、Kirk W. Johnson、Dirksen E. Bussiere

  DOI：10.1021/acs.jmedchem.7b00922

  日期：2017.10.26

  -yl)[2-(2-pyridylamino)ethyl]amine analogues which are inhibitors of human glycogen synthase kinase 3 (GSK3). We developed efficient synthetic routes to explore a wide variety of substitution patterns and convergently access a diverse array of analogues. Compound 1 (CHIR-911, CT-99021, or CHIR-73911) emerged from an exploration of heterocycles at the C-5 position, phenyl groups at C-4, and a variety

  为了鉴定新的抗糖尿病药，我们发现了一种新型的（5-咪唑-2--2-基-4-苯基嘧啶-2-基）[2-（2-吡啶基氨基）乙基]胺类似物，它们是人类的抑制剂。糖原合酶激酶3（GSK3）。我们开发了有效的合成路线来探索各种取代模式，并会聚各种类似物。化合物1（CHIR-911，CT-99021或CHIR-73911）来自对C-5位置的杂环，C-4的苯基以及C处连接的各种不同取代的连接基和氨基吡啶部分的探索-2位置。这些化合物表现出GSK3 IC 50在低纳摩尔范围内和出色的选择性。它们激活表达胰岛素受体的CHO-IR细胞和原代大鼠肝细胞中的糖原合酶。在2型糖尿病的啮齿动物模型中对先导化合物1和2（CHIR-611或CT-98014）的评估表明，单次口服剂量可在60分钟内降低高血糖症，增强胰岛素刺激的葡萄糖转运，并改善葡萄糖的处置而不增加胰岛素水平。
• SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES
  申请人：Siegel Stephan

  公开号：US20100113441A1

  公开（公告）日：2010-05-06

  The invention relates to substituted imidazopyrimidines and triazolopyrimidines, to methods for the production thereof, and to the use of same for producing medicaments for the treatment and/or prophylaxis of diseases, especially haematological diseases, preferably leucopenia and neutropenia.

  本发明涉及取代的咪唑[嘧啶]和三唑[嘧啶]，及其生产方法，以及用于生产用于治疗和/或预防疾病，特别是血液病，尤其是白血球减少症和粒细胞减少症的药物的应用。